{
    "pmcid": "9900178",
    "qa_pairs": {
        "What challenge does the study highlight regarding the vaccine's cross-reactivity with SARS-CoV-2 variants?": [
            "Limited cross-reactivity with the Omicron variant",
            "Inability to neutralize the Delta variant",
            "Reduced efficacy against the Alpha variant",
            "No cross-reactivity with the Beta variant"
        ],
        "What immune system component did the vaccine-induced antibodies activate, according to the study?": [
            "Complement system",
            "Natural killer cells",
            "Dendritic cells",
            "Macrophages"
        ],
        "What potential advantage of nanobodies is emphasized for rapid deployment during outbreaks?": [
            "Stability and ease of production",
            "Higher binding affinity",
            "Longer half-life in circulation",
            "Greater specificity for viral proteins"
        ],
        "What was the primary adjuvant used in the SARS-CoV-2 spike protein vaccine tested on Syrian hamsters?": [
            "Aluminium hydroxide (Alhydrogel\u00ae)",
            "Calcium phosphate",
            "Squalene-based adjuvant",
            "Monophosphoryl lipid A"
        ],
        "Which immune mechanism, besides neutralizing antibodies, is suggested to contribute to the partial protection observed in the study?": [
            "Fc-mediated functions or T-cell responses",
            "Increased cytokine production",
            "Enhanced B-cell proliferation",
            "Interferon gamma release"
        ]
    }
}